Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer

Publisher： Karger

E-ISSN： 1421-9867|89|1|18-23

ISSN： 0012-2823

Source： Digestion, Vol.89, Iss.1, 2014-01, pp. : 18-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti‐epidermal or anti‐vascular endothelial growth factor as first‐line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients

By  

Journal Of Cachexia Sarcopenia And Muscle, Vol. 6, Iss. 3, 2015-09 ,pp. : 231-236

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adhesion Molecules Affected by Treatment of Lung Cancer Cells with Epidermal Growth Factor

By Fonseca Fernando  

Lung, Vol. 189, Iss. 5, 2011-10 ,pp. : 383-389

Springer Publishing Company

Access to resources Recommend Favorite

Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer

By  

Digestion, Vol. 88, Iss. 3, 2013-10 ,pp. : 172-181

Karger

Access to resources Recommend Favorite

Reduced Expression of Epidermal Growth Factor Receptor-Related Protein in Hepatocellular Carcinoma: Implications for Cancer Growth

By  

Digestion, Vol. 69, Iss. 4, 2004-08 ,pp. : 219-224

Karger

Access to resources Recommend Favorite

Actions of Epidermal Growth Factor and Its Receptor in the Thyroid

By Nilsson M.  

Trends in Endocrinology and Metabolism, Vol. 6, Iss. 5, 1995-07 ,pp. : 175-182

Elsevier

Access to resources Recommend Favorite